A Phase 3 Clinical Study of QL2106 Injection

Inclusion Criteria: * 1.Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention 2.Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline 3.Total psoriasis area and severity index (PASI) \>=12 at screening and baseline 4.Total investigator global assessment (IGA) \>=3 at screening and baseline 5.Candidate for phototherapy or systemic treatment for plaque psoriasis Exclusion Criteria: * 1.Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular) 2.Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)